

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A luminal prosthesis comprising:
a scaffold which is implantable within a body lumen; and
means on the scaffold for releasing a substance, wherein the substance is released over a predetermined time pattern comprising an initial phase wherein a substance delivery rate is below a threshold level and a subsequent phase wherein the substance delivery rate is above a threshold level.
2. (Original) A luminal prosthesis as in claim 1, wherein the scaffold is a stent or graft.
3. (Original) A luminal prosthesis as in claim 1, wherein the scaffold is implantable in a blood vessel.
4. (Withdrawn) A luminal prosthesis as in claim 1, wherein the means for releasing the substance comprises a matrix formed over at least a portion of the scaffold.
5. (Withdrawn) A luminal prosthesis as in claim 4, wherein the matrix is composed of a material which undergoes degradation in a vascular environment.
6. (Withdrawn) A luminal prosthesis as in claim 5, wherein the matrix degrades by surface degradation.
7. (Withdrawn) A luminal prosthesis as in claim 5, wherein the matrix degrades by bulk degradation.

8.-73. (Canceled).

74. (Currently Amended) A device for intracorporeal use, comprising:
a structure; and

at least ~~lease~~ one source of at least one therapeutic capable agent associated with the structure, wherein the device is configured to release the therapeutic capable agent at a plurality of release rates.

75. (Original) The device of Claim 74 wherein the source is configured to provide the at least one therapeutic capable agent to a targeted intracorporeal site within an intracorporeal body.

76. (Original) The device of Claim 75 wherein the targeted intracorporeal site comprises a body lumen.

77. (Original) The device of Claim 75 wherein the targeted intracorporeal site comprises a body organ.

78. (Original) The device of Claim 75 wherein the device is configured for implanting at the targeted intracorporeal site supplying blood to a susceptible tissue site.

79. (Original) The device of Claim 75 wherein the targeted intracorporeal site includes a susceptible tissue site.

80. (Original) The device of Claim 75 or 76 wherein the device comprises a vascular prosthesis.

81. (Original) The device of Claim 80 wherein the vascular prosthesis comprises an expandable structure.

82. (Original) The device of Claim 81 wherein the vascular prosthesis comprises a graft.

83. (Original) The device of Claim 81 wherein the vascular prosthesis comprises a stent.
84. (Original) The device of Claim 83 wherein prosthesis comprises a scaffold formed at least in part from an open lattice.
85. (Original) The device of Claim 75 wherein source is the therapeutic capable agent.
86. (Original) The device of Claim 81 wherein the expandable structure has a luminal and a tissue facing surface.
87. (Original) The device of Claim 86 wherein the therapeutic capable agent is associated with the expandable structure on at least one of the expandable structure luminal or tissue facing surfaces.
88. (Original) The device of Claim 86 wherein the expandable structure has an interior.
89. (Original) The device of Claim 88 wherein therapeutic capable agent is associated with the interior of the expandable structure.
90. (Currently Amended) The device of Claim 75 ~~or 87~~ wherein the ~~expandable~~ structure is formed from an at least partially degradable material.
91. (Original) The device of Claim 90 wherein the at least partially degradable material is at least partially biodegradable.
92. (Currently Amended) The device of Claim 91 ~~90~~ wherein the at least partially biodegradable material comprises a metal or alloy degradable in the corporeal body.
93. (Currently Amended) The device of Claim 92 wherein the metal or alloy ~~alloy~~ comprises stainless steel.

94. (Currently Amended) The device of Claim 93 wherein the therapeutic capable agent is made available to a ~~the~~ susceptible tissue site as the stainless steel degrades within the corporal body over time.

95. (Original) The device of Claim 85 wherein the therapeutic capable agent comprises a polymeric material formed at least in part from therapeutic capable agent.

96. (Original) The device of Claim 95 wherein the therapeutic capable agent units are disassociated in the corporeal body.

97. (Original) The device of Claim 95 wherein the therapeutic capable agent units are disassociated in a vascular environment.

98. (Original) The device of Claim 95 wherein the therapeutic capable agent units are disassociated over time.

99. (Original) The device of Claim 85 wherein the source is a polymeric material including the therapeutic capable units associated with a polymeric backbone.

100. (Original) The device of Claim 85 wherein the source is a polymeric material including the therapeutic capable units associated with a metallic backbone.

101. (Canceled).

102. (Currently Amended) The device of Claim 74 ~~101~~ wherein the release rates provides a sustainable level of therapeutic capable agent to the susceptible tissue site.

103.-106. (Canceled).

107. (Withdrawn) The device of Claim 74 ~~101~~ wherein the release rates are is pre-defined.

108. (Canceled).

109. (Withdrawn) The device of Claim ~~74~~ 108 wherein the plurality of rates includes at least two rates selected from the group consisting of substantially constant, decreasing, increasing, substantially non-releasing.

110. (Original) The device of Claim 87 wherein the source is disposed adjacent at least one of the luminal or tissue facing surfaces of the expandable structure.

111. (Withdrawn) The device of Claim 110 wherein the source comprises a matrix including the therapeutic capable agent.

112. (Currently Amended) The device of Claim 75 ~~or 81~~ further including a rate-controlling element.

113. (Withdrawn) The device of Claim 112 wherein the source comprises the rate-controlling element.

114. (Withdrawn) The device of Claim 112 wherein the rate-controlling element is disposed adjacent at least a portion of the source.

115. (Withdrawn) The device of Claim 114 wherein at least a portion of the rate-controlling element forms a matrix with the therapeutic capable agent.

116. (Original) The device of Claim 114 wherein the rate-controlling element forms the outer most layer of the device.

117. (Currently Amended) The device of Claim 112 wherein the rate-controlling element is disposed adjacent at least a portion of the ~~expandable~~ structure.

118. (Currently Amended) The device of Claim ~~112, 113, 114, 116, or 117~~ wherein the rate-controlling element is formed from a material selected from the group consisting of polymeric, metallic, bioactive compounds, and non-bioactive compounds.

119. (Original) The device of Claim 118 wherein the rate-controlling element material comprises a polymeric material.

120. (Withdrawn) The device of Claim 119 further comprising a second rate-controlling element disposed adjacent at least a portion of the first rate-controlling element.

121. (Withdrawn) The device of Claim 118 wherein the rate-controlling element is formed from a biodegradable material.

122. (Original) The device of Claim 118 wherein the rate-controlling element is formed from a material selected from the group consisting of poly(lactic acid), poly(glycolic acid) and copolymers, poly dioxanone, poly (ethyl glutamate), poly (hydroxybutyrate), polyhydroxyvalerate and copolymers, polycaprolactone, polyanhydride, poly(ortho esters); poly (iminocarbonates), polycyanoacrylates, polyphosphazenes, copolymers and other aliphatic polyesters, or suitable copolymers thereof including copolymers of poly-L-lactic acid and poly-ε-caprolactone; mixtures, copolymers, and combinations thereof.

123. (Withdrawn) The device of Claim 121 wherein the therapeutic capable agent is released by surface degradation or hydrolysis of the rate-controlling element.

124. (Withdrawn) The device of Claim 121 wherein the therapeutic capable agent is released by bulk degradation of the rate-controlling element.

125. (Original) The device of Claim 118 wherein the rate-controlling element is formed from a non-biodegradable or slow degrading material.

126. (Original) The device of Claim 118 wherein the rate-controlling element is formed from a material selected from the group consisting of polyurethane, polyethylenes imine, cellulose acetate butyrate, ethylene vinyl alcohol copolymer, silicone, polytetrafluorethylene (PTFE), parylene, parylast, poly (methyl methacrylate butyrate), poly-N-butyl methacrylate, poly (methyl methacrylate), poly 2-hydroxy ethyl methacrylate, poly ethylene glycol methacrylates, poly vinyl chloride, poly(dimethyl siloxane),

poly(tetrafluoroethylene), poly (ethylene oxide), poly ethylene vinyl acetate, poly carbonate, poly acrylamide gels, N-vinyl-2-pyrrolidone, maleic anhydride, Nylon, cellulose acetate butyrate (CAB) and the like, including other synthetic or natural polymeric substances; mixtures, copolymers, and combinations thereof.

127. (Original) The device of Claim 118 wherein the rate-controlling element is formed from a material selected from the group consisting of silicone, polytetrafluoroethylene, parylast, polyurethane, parylene, cellulose acetate butyrate; mixtures, copolymers and combinations thereof.

128. (Withdrawn) The device of Claim 118 wherein the rate-controlling element is formed from a natural material.

129. (Withdrawn) The device of Claim 118 wherein the rate-controlling element is formed from a material selected from the group consisting of fibrin, albumin, collagen, gelatin, glycosoaminoglycans, chondroitin, oligosaccharides & poly saccharides, phospholipids, phosphorylcholine, glycolipids, proteins, amino acids, cellulose, and mixtures, copolymers, or combinations thereof.

130. (Original) The device of Claim 125 wherein the therapeutic capable agent is released by diffusion through the rate-controlling element.

131. (Withdrawn) The device of Claim 118 wherein the rate-controlling element comprises a metallic material.

132. (Withdrawn) The device of Claim 118 wherein the rate-controlling element is formed from a material selected from the group consisting titanium, chromium, Nitinol, gold, stainless steel, alloys, and combinations thereof.

133. (Withdrawn) The device of Claim 132 wherein the metals or alloys are at least two and having different galvanic potential.

134. (Withdrawn) The device of Claim 118 wherein the rate-controlling element includes a plurality of layers.

135. (Withdrawn) The device of Claim 134 wherein at least one of the rate-controlling element plurality of layers includes the therapeutic capable agent.

136. (Withdrawn) The device of Claim 135 wherein the layers other than the at least one layer includes the same or a different therapeutic capable agent.

137. (Withdrawn) The device of Claim 86 wherein the source is a reservoir disposed adjacent the expandable structure.

138. (Withdrawn) The device of Claim 137 wherein the reservoir is at least partially on an exterior of the expandable structure.

139. (Withdrawn) The device of Claim 137 wherein the reservoir is at least partially in an ~~the~~ interior of the expandable structure.

140. (Withdrawn) The device of Claim 137 wherein the reservoir is at least partially on either or both the luminal and the tissue facing surfaces of the expandable structure.

141. (Withdrawn) The device of Claim 137 wherein the reservoir is at least partially in the expandable structure.

142. (Withdrawn) The device of Claim 140 ~~138 or 139~~ wherein a rate-controlling element is disposed at least partially adjacent the reservoir.

143. (Withdrawn) The device of Claim ~~140 or~~ 141 wherein a rate-controlling element is disposed at least partially over the reservoir.

144. (Withdrawn) The device of 113 or 115 wherein the rate-controlling element has thickness ranging from about 10 nm to about 100 μm ~~um~~.

145. (Withdrawn) The device of Claim 144 wherein the rate-controlling element has thickness ranging from about 50 nm to about 100 μm ~~um~~.

146. (Withdrawn) The device of Claim 144 wherein the rate-controlling element has thickness ranging from about 100 nm to about 50 μm ~~um~~.

147. (Withdrawn) The device of Claim 144 wherein the rate-controlling element has thickness ranging from about 100 nm to about 10 μm ~~um~~.

148. (Withdrawn) The device of Claim 144 wherein the device further comprises a bio-compatible outer layer.

149. (Withdrawn) The device of Claim 148 wherein the bio-compatible layer is formed from a material consisting of polyethylene glycol, polyethylene oxide, hydrogels, silicone, polyurethanes, heparin, and combinations thereof.

150. (Currently Amended) A device for intracorporeal use, comprising:
an expandable member having at least one of luminal and tissue facing surfaces;
and
at least ~~lease~~ one source of at least one therapeutic capable agent disposed adjacent at least one of the luminal or tissue facing surfaces, wherein the device is configured to release the therapeutic capable agent at a phase to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 0.001 ng of therapeutic capable agent / mg of tissue to about 100 μg of therapeutic capable agent / mg of tissue.

151. (Original) The device of Claim 150 wherein the therapeutic capable agent comprises at least one agent selected from the group consisting of immunosuppressants, anti-inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, calcium channel blockers, anti-neoplastics, antibodies, anti-thrombotic agents, anti-platelet agents, IIb/IIIa agents, antiviral agents, and a combination thereof.

152. (Original) The device of Claim 151 wherein the therapeutic capable agent has more than one therapeutic effect.

153. (Original) The device of Claim 152 wherein the therapeutic capable agent has anti-inflammatory and immunosuppressant effects.

154. (Original) The device of Claim 152 wherein the therapeutic capable agent has anti-inflammatory and anti-proliferative effects.

155. (Original) The device of Claim 152 wherein the therapeutic capable agent has immunosuppressants and anti-proliferative effects.

156. (Original) The device of Claim 152 wherein the therapeutic capable agent has immunosuppressive, anti-proliferative, and anti-inflammatory effects.

157. (Original) The device of Claim 151 wherein the therapeutic capable agent is at least one agent selected from the group consisting of mycophenolic acid, mycophenolate mofetil, mizoribine, methylprednisolone, dexamethasone, Certican, rapamycin, Triptolide, Methotrexate, Benidipine, Ascomycin, Wortmannin, LY294002, Camptothecin, Topotecan, hydroxyurea, Tacrolimus (FK 506), cyclophosphamide, cyclosporine, daclizumab, azathioprine, prednisone, Gemcitabine, derivatives and combinations thereof.

158. (Original) The device of Claim 151 or 157 wherein the at least one agent includes an active compound, the pro-drug of the active compound, a metabolite of the active compound, a derivative of the active compound, or a combination thereof.

159. (Withdrawn) The device of Claim 150 wherein source further includes another compound.

160. (Withdrawn) The device of Claim 159 wherein another compound is another therapeutic capable agent.

161. (Withdrawn) The device of Claim 159 wherein the another compound is an enabling compound.

162. (Withdrawn) The device of Claim 159 wherein the another compound is selected from the group consisting of anti-cancer agents; chemotherapeutic agents; thrombolytics; vasodilators; antimicrobials or antibiotics antimitotics; growth factor antagonists; free readical scavengers; biologic agents; radiotherapeutic agents; radiopaque agents; radiolabelled agents; anti-coagulants such as heparin and its derivatives; anti-angiogenesis drugs; angiogenesis drugs; PDGF-B and/or EGF inhibitors; anti-inflammatories including psoriasis drugs; anti-platelet agents including , cyclooxygenase inhibitors such as acetylsalicylic acid, ADP inhibitors ticlopidine phosphodiesterase III inhibitors, glycoprotein IIb/IIIa agents; eptifibatides, and adenosine reuptake inhibitors; healing and/or promoting agents including anti-oxidants, nitrogen oxide donors; antiemetics; antinauseants; derivatives and combinations thereof.

163. (Withdrawn) The device of Claim 159 wherein the another compound is selected from the group consisting of heparin and its derivatives; Thalidomide; riboflavin; tiazofurin; zafurin; acetylsalicylic acid, clopidogrel such as Plavix, ticlopidine such as ticlid, cilostazol such as Pletal, abciximab such as Rheopro; eptifibatide such as Integrilin, dipyridmoles; NSAID, TaxolTM, Actinomycine DTM; derivatives and combinations thereof.

164. (Withdrawn) The device of Claim 159 wherein the another compound is selected from the group consisting of NSAID, TaxolTM, Actinomycine DTM.

165. (Withdrawn) The device of Claim 159 wherein the another compound is a magnetic particle.

166. (Withdrawn) The device of Claim ~~151, 157, 158, or 161~~ wherein the device is configured to release the therapeutic capable agent in response to an external source of energy.

167. (Withdrawn) The device of Claim 166 wherein the external source of energy is ultrasound, magnetic resonance imaging, magnetic field, radio frequency, temperature change, electromagnetic, x-ray, heat, vibration, gamma radiation, microwave, or a combination thereof.

168. (Withdrawn) The device of Claim 166 wherein the external source of energy is a magnetic field.

169. (Withdrawn) The device of Claim 159 wherein the device is configured to release the another compound prior to, concurrent with, or subsequent to the release of the therapeutic capable agent.

170. (Canceled).

171. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a rate between about 0.001 μg ~~μg~~ to about 200 μg ~~μg~~ /day.

172. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a rate between about 0.5 μg ~~μg~~ to about 200 μg ~~μg~~ /day.

173. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a rate between about 1 μg ~~μg~~ to about 100 μg ~~μg~~ /day.

174. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a rate between about 10 μg ~~μg~~ to about 60 μg ~~μg~~ /day.

175. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a rate between about 1 μg ~~μg~~ to about 60 μg ~~μg~~ /day.

176. (Currently Amended) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at different phases.

177. (Original) The device of Claim 176 wherein the device is configured to release the therapeutic capable agent at an initial phase having a lower rate of release than a subsequent phase.

178. (Original) The device of Claim 176 wherein the device is configured to release the therapeutic capable agent at an initial phase having a higher rate of release than a subsequent phase.

179. (Original) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0 to about 99% of a subsequent rate of release of a subsequent phase.

180. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0 to about 90% of a subsequent rate of release of a subsequent phase.

181. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0 to about 75% of a subsequent rate of release of a subsequent phase.

182. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0 to about 50% of a subsequent rate of release of a subsequent phase.

183. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0 to about 50 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 0.01 μg to about 200 μg /day.

184. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0.001 to about 50 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 0.01 μg to about 200 μg /day.

185. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0.1 to about 30 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 0.01 μg to about 200 μg /day.

186. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 1 to about 20 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 0.01 μg to about 200 μg /day.

187. (Withdrawn) The device of Claim 177 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 0.1 to about 30 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 1.0 μg to about 100 μg /day.

188. (Withdrawn) The device of Claim 178 ~~180~~ wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 10 to about 300 μg /day, and a subsequent phase having a subsequent rate of release ranging from about 0.1 to about 100 μg /day.

189. (Withdrawn) The device of Claim 178 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 40 to about 300 μg ~~μg~~ /day, and a subsequent phase having a subsequent rate of release ranging from about 0.5 to 40 μg ~~μg~~ /day.

190. (Withdrawn) The device of Claim 178 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 40 to about 200 μg ~~μg~~ /day, and a subsequent phase having a subsequent rate of release ranging from about 10 to 40 μg ~~μg~~ /day.

191. (Withdrawn) The device of Claim 178 wherein the device is configured to release the therapeutic capable agent at an initial phase having an initial rate of release ranging from about 40 to about 200 μg ~~μg~~ /day, and a subsequent phase having a subsequent rate of release ranging from about 0.5 to 40 μg /day.

192. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a substantially constant rate ranging from about 0.01 μg ~~μg~~ to 200 μg ~~μg~~ /day.

193. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a total amount ranging from about 0.1 μg ~~μg~~ to about 10 g.

194. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a total amount ranging from about 0.1 μg ~~μg~~ to about 10 mg.

195. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a total amount ranging from about 1 μg ~~μg~~ to about 2 mg.

196. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a total amount ranging from about 10 μg ~~μg~~ to about 2 mg.

197. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a total amount ranging from about 50 μg ~~μg~~ to about 1 mg.

198. (Canceled).

199. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to deliver the therapeutic capable agent at a phase to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 1 ng of therapeutic capable agent / mg of tissue to about 100 μg ~~μg~~ of therapeutic capable agent / mg of tissue.

200. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to deliver the therapeutic capable agent at a phase to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 1 ng of therapeutic capable agent / mg of tissue to about 10 μg ~~μg~~ of therapeutic capable agent / mg of tissue.

201. (Withdrawn) The device of Claim 150 ~~158~~ wherein the device is configured to release the therapeutic capable agent at a phase to a mammalian intracorporeal body to effectuate a mammalian blood concentration ranging from about 1 ng of therapeutic capable agent / ml of blood to about 50 μg ~~μg~~ of therapeutic capable agent / ml of blood.

202. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a phase to a mammalian intracorporeal body to effectuate a mammalian blood concentration ranging from about 1 ng of therapeutic capable agent / ml of blood to about 20 μg ~~μg~~ of therapeutic capable agent / ml of blood.

203. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to release the therapeutic capable agent at a phase to a mammalian intracorporeal body to effectuate a mammalian blood concentration ranging from about 2 ng of therapeutic capable agent / ml of blood to about 12 μg ~~μg~~ of therapeutic capable agent / ml of blood.

204. (Withdrawn) The device of Claim 201, 202, or 203 wherein the phase is within the first 24 hours after the implantation of the device in the mammalian intracorporeal body.

205. (Withdrawn) The device of Claim 201, 202, or 203 wherein the concentration is a peak concentration.

206. (Withdrawn) The device of Claim 150 ~~198~~ or 199 wherein the phase is a first phase.

207. (Withdrawn) The device of Claim 206 wherein the device is configured to deliver the therapeutic capable agent at a second phase to the susceptible tissue site of the mammalian intracorporeal body to effectuate a mammalian tissue concentration of the therapeutic capable agent ranging from about 0.001 ng of therapeutic capable agent / mg of tissue to about 100 μg ~~μg~~ of therapeutic capable agent / mg of tissue.

208. (Withdrawn) The device of Claim 207 wherein the tissue concentration ranges from about 1 ng of therapeutic capable agent / mg of tissue to about 10 μg ~~μg~~ of therapeutic capable agent /mg of tissue.

209. (Withdrawn) The device of Claim 150 ~~170~~ wherein device is configured to release the therapeutic capable agent at a substantially constant rate ranging from about 0.01 μg ~~μg~~ to 200 μg ~~μg~~ /day.

210. (Withdrawn) The device of Claim 176 wherein device is configured to deliver the therapeutic capable agent at an initial and a subsequent phase.

211. (Withdrawn) The device of Claim 210 ~~476~~ wherein at the initial phase the release of the therapeutic capable agent is delayed.

212. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last less than about 24 weeks.

213. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last less than about 12 weeks.

214. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last from about 1 hour to about 24 weeks.

215. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last from about 1 hour to about 8 weeks.

216. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last from about 12 hours to about 2 weeks.

217. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the initial phase is configured to last from about 1 day to about 1 week.

218. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the subsequent phase is configured to last from about 4 hours to about 8 weeks.

219. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the subsequent phase is configured to last from about 1 hour to about 8 weeks.

220. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the subsequent phase is configured to last from about 1 hour to about 12 weeks.

221. (Withdrawn) The device of Claim 210 ~~476~~, or 211 wherein the duration of the subsequent phase is configured to last from about 1 hour to about 1 day.

222. (Withdrawn) The device of Claim 210 ~~176~~ wherein the duration of the subsequent phase is configured to last from about 1 day to about 12 weeks.

223. (Withdrawn) The device of Claim 210 ~~176~~ wherein the duration of the subsequent phase is configured to last from about 2 days to about 8 weeks.

224. (Withdrawn) The device of Claim 210 ~~176~~ wherein the duration of the subsequent phase is configured to last from about 3 days to about 50 weeks.

225. (Withdrawn) The device of Claim 210 ~~176~~ wherein the duration of the subsequent phase is configured to last from about 3 days to about 30 days.

226. (Original) The device of Claim 178 wherein the duration of the initial phase is configured to last from about 1 day to about 7 days.

227. (Withdrawn) The device of Claim 178 wherein the duration of the initial phase is configured to last from about 1 day to about 30 days.

228. (Withdrawn) The device of Claim 178 wherein the duration of the subsequent phase is configured to last from about 2 days to about 45 days.

229. (Currently Amended) The device of Claim 226 wherein the device is configured to deliver the therapeutic capable agent at the initial phase to a susceptible tissue site of a mammalian intracorporal body to effectuate a mammalian tissue concentration of the therapeutic capable agent ranging from about 10 ng / mg to about 100 μ g ~~ug~~ / mg.

230. (Withdrawn) The device of Claim 228 wherein the device is configured to deliver the therapeutic capable agent at the initial phase to a susceptible tissue site of a mammalian intracorporal body to effectuate a mammalian tissue concentration of the therapeutic capable agent ranging from about 10 ng / mg to about 100 μ g ~~ug~~ / mg.

231. (Withdrawn) The device of Claim 150 ~~170~~ wherein the device is configured to have a termination phase delivering the therapeutic capable agent to a mammalian

intracorporeal body at a rate less than a rate of clearance of the intracorporeal body of the therapeutic capable agent.

232. (Withdrawn) The device of Claim 231 wherein the termination phase has a duration of about 14 days.

233. (Withdrawn) The device of Claim 231 wherein the rate of clearance is about 1 ng to about 100 ng per mg of tissue per day.

234. (Withdrawn) The device of Claim 231 wherein the rate of clearance is about 80 ng per mg of tissue per day.

235. (Withdrawn) The device of Claim 231 wherein the rate of clearance is about 10 ng per mg of tissue per day.

236. (Original) The device of Claim 150 wherein the source is associated with the expandable structure by coating, spraying, dipping, vapor deposition, plasma deposition, or painting of the source onto or in the expandable structure.

237. (Withdrawn) The device of Claim 236 wherein the source is mixed in a solvent selected from the group consisting of methanol, DMSO, CO₂.

238.-271. (Canceled).

272. (Previously Presented) The device of Claim 118 wherein the rate-controlling element comprises parylast or parylene.

273. (Canceled).

274. (New) The device of claim 1, wherein the means for releasing the substance comprises a rate-controlling element.

275. (New) The device of claim 274, wherein the rate-controlling element comprises parylene.